BiondVax Pharmaceuticals Statistics Share Statistics BiondVax Pharmaceuticals has 3.65M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 3.65M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 2.72M Failed to Deliver (FTD) Shares 76 FTD / Avg. Volume 0.2%
Short Selling Information The latest short interest is 2.18K, so 0% of the outstanding
shares have been sold short.
Short Interest 2.18K Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -50.66 and the forward
PE ratio is null.
BiondVax Pharmaceuticals's PEG ratio is
0.51.
PE Ratio -50.66 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio -15.28 P/FCF Ratio -3.32 PEG Ratio 0.51
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for BiondVax Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 6.15,
with a Debt / Equity ratio of -12.24.
Current Ratio 6.15 Quick Ratio 6.15 Debt / Equity -12.24 Debt / EBITDA -2.05 Debt / FCF -2.66 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-16.09K Employee Count 33 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -5.26M Effective Tax Rate 90.84%
Stock Price Statistics The stock price has increased by 70% in the
last 52 weeks. The beta is 2.37, so BiondVax Pharmaceuticals's
price volatility has been higher than the market average.
Beta 2.37 52-Week Price Change 70% 50-Day Moving Average 1.22 200-Day Moving Average 1.92 Relative Strength Index (RSI) 16.45 Average Volume (20 Days) 38,939
Income Statement
Revenue n/a Gross Profit n/a Operating Income -11.06M Net Income -531K EBITDA -10.5M EBIT -11.06M Earnings Per Share (EPS) -0.2
Full Income Statement Balance Sheet The company has 14.07M in cash and 21.54M in
debt, giving a net cash position of -7.47M.
Cash & Cash Equivalents 14.07M Total Debt 21.54M Net Cash -7.47M Retained Earnings -115.83M Total Assets 19.9M Working Capital 5.88M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -7.26M
and capital expenditures -836K, giving a free cash flow of -8.1M.
Operating Cash Flow -7.26M Capital Expenditures -836K Free Cash Flow -8.1M FCF Per Share -3.13
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields BVXV does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for BVXV.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Nov 25, 2022. It was a
backward
split with a ratio of 1:10.
Last Split Date Nov 25, 2022 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -9.67 Piotroski F-Score 4
